Indeed, piperlongumine activated NRF2 in CTOSs but not in fibroblasts, suggesting that GSTπ inhibition is more detrimental against cancer cells due to GSTP1 up‐regulation (Figs. 1, S5 and S6). This evidence concerns the gene NFE2L2 and cancer.